18.5: Calcium Channel Blockers

Pharmacology for Nurses · LibreTexts

0%

Contents

    Text

    Size
    100%
    Theme
    Typeface
    Line length
    Spacing

    Read aloud

    How

    Speed: 1×
    Light up
    Highlight

    Symbols: Mulberry Symbols, © 2018–2026 Steve Lee, CC BY-SA 4.0 (licence, the set), the site's own copies.

    From LibreTexts, under CC BY 4.0, as the source states it; its equations are written in TeX, which the PDF shows typeset. This page at LibreTexts.

    18.5: Calcium Channel Blockers
    Learning Objectives

    By the end of this section, you should be able to:

    • 18.5.1 Identify the characteristics of the calcium channel blocker drugs used to treat hypertension and angina.
    • 18.5.2 Explain the indications, actions, adverse reactions, and interactions of the calcium channel blocker drugs used to treat hypertension and angina.
    • 18.5.3 Describe nursing implications of calcium channel blocker drugs used to treat hypertension and angina.
    • 18.5.4 Explain the client education related to calcium channel blocker drugs used to treat hypertension and angina.

    Introduction and Use

    Calcium channel blockers are a classification of drug that blocks calcium from entering cells by binding to long-acting voltage-gated calcium channels in the heart, smooth muscle, and pancreas. Calcium causes vasoconstriction. Calcium channel blockers inhibit calcium and allow for vasodilation, thereby causing the heart rate to slow and blood pressure to lower. Calcium channel blockers are commonly used to treat hypertension, angina, and arrhythmias.

    Calcium channel blockers are classified as dihydropyridines or nondihydropyridines. Dihydropyridines are peripheral vasodilators that lower blood pressure and heart rate; they are used to treat post-intracranial hemorrhage, vasospasm, and migraines. In addition to their action on the peripheral vasculature, nondihydropyridines inhibit the sinoatrial and AV nodes, slowing cardiac conduction and heart rate and decreasing oxygen demand.

    Calcium channel blockers may be used alone or in combination with other drugs. They are highly protein bound, which increases the volume of distribution within the body. Calcium channel blockers are available in long- and short-acting formulas.

    Special Considerations

    Calcium Channel Blockers

    Calcium channel blockers are among the most effective antihypertensive classifications of drugs for use in non-Hispanic Black adults.

    (Source: Abrahamowicz et al., 2023)

    Safety Alert

    Calcium Channel Blockers

    Abrupt discontinuation of calcium channel blockers may cause chest pain.

    Table 18.9 lists common calcium channel blockers and typical routes and dosing for adult clients.

    Drug Routes and Dosage Ranges
    Amlodipine
    (Norvasc)
    5–10 mg orally daily.
    Diltiazem
    (Cardizem)
    Initial dosage: 30 mg orally 4 times daily, before meals and at bedtime. Increase dosage gradually (given in divided doses 3–4 times daily) at 1- to 2-day intervals until optimum response is obtained.
    Average optimum dosage: 180–360 mg daily.
    Nicardipine
    (Cardene)
    Immediate release: 20–40 mg orally 3 times daily.
    Sustained release: 30–60 mg daily; maximum dose 120 mg daily.
    Intravenous (IV) infusion: 5–15 mg hourly.
    Nifedipine
    (Procardia)
    Immediate release: Starting dose 10 mg orally 3 times daily. The usual effective dose range is 10–20 mg 3 times daily. Doses above 120 mg daily are rarely necessary. More than 180 mg daily is not recommended.
    Sustained release: 30–60 mg orally daily; maximum dose 120 mg daily.
    Verapamil
    (Calan SR, Verelan)
    Immediate release: 40–120 mg 3 times daily.
    Sustained release: 180–240 mg daily.
    IV: Follow manufacturer’s instructions and health care provider’s orders.
    Table 18.9 Drug Emphasis Table: Calcium Channel Blockers (source: https://dailymed.nlm.nih.gov/dailymed/)

    Adverse Effects and Contraindications

    Adverse effects of calcium channel blockers include dizziness, constipation, palpitations, fatigue, flushing, nausea, rash, headache, and swelling in the legs and feet. Serious side effects include thrombocytopenia, hypotension, and hyperglycemia. Clients with a hypersensitivity to calcium channel blockers or their components should not use this classification of drug. Other contraindications include sick sinus syndrome (except in clients with an artificial pacemaker), severe hypotension, a history of myocardial infarction, or a history of pulmonary congestion.

    Table 18.10 is a drug prototype table for calcium channel blockers featuring amlodipine. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.

    Drug Class
    Calcium channel blocker

    Mechanism of Action
    Inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, thereby decreasing peripheral vascular resistance and reducing blood pressure
    Drug Dosage
    5–10 mg orally daily.
    Indications
    To control hypertension
    In the treatment of angina

    Therapeutic Effects
    Lowers blood pressure
    Increases blood supply and oxygen to the heart
    Drug Interactions
    Simvastatin
    Clarithromycin
    Ritonavir

    Food Interactions
    No significant interactions
    Adverse Effects
    Peripheral edema
    Headache
    Fatigue
    Palpitations
    Hypotension
    Dizziness
    Nausea
    Flushing
    Pruritus
    Skin rash
    Muscle cramps
    Erectile dysfunction
    Contraindications
    Hypersensitivity

    Caution:
    Aortic stenosis
    Symptomatic hypotension
    Angina
    Myocardial infarction
    Hepatic impairment
    Pregnancy
    Breastfeeding
    Table 18.10 Drug Prototype Table: Amlodipine (source: https://dailymed.nlm.nih.gov/dailymed/)

    Nursing Implications

    The nurse should do the following for clients who are taking calcium channel blockers:

    • Monitor the client for interactions because many medications and herbal supplements, such as St. John’s wort, interact with calcium channel blockers. Grapefruit juice also can affect the action of certain calcium channel blockers.
    • Assess and monitor the client for adverse effects and contraindications.
    • Provide client teaching regarding the drug and when to call the health care provider. See below for client teaching guidelines.

    Client Teaching Guidelines

    The client taking a calcium channel blocker should:

    • Report side effects such as severe headaches, dizziness, lightheadedness, flushing, nausea, and leg swelling to their health care provider.
    • Take this medication with food to avoid GI upset, nausea, and vomiting.

    FDA Black Box Warning

    Calcium Channel Blockers

    Immediate release nifedipine, a potent calcium blocker, may increase the risk of myocardial infarction, stroke, and arrhythmias.

    Unfolding Case Study

    Part B

    Read the following clinical scenario to answer the questions that follow. This case study is a follow-up to Case Study Part A.

    Hahn Tran follows up with her health care provider one week later to get the results of her diagnostic studies. The health care provider diagnose her with hypertension stage 2 and starts her on enalapril, an ACE inhibitor. The nurse then teaches Hahn about this new drug.

    3.
    Which instruction about enalapril will the nurse give Hahn?
    1. Take this medication with a meal.
  1. Do not take this medication if your heart rate is less than 60 beats/minute.
  2. Avoid salt substitutes that contain potassium while taking this medication.
  3. Avoid eating grapefruit while taking this medication.
  4. Exercise \(\PageIndex{4}\)

    Avoid salt substitutes that contain potassium while taking this medication.

  5. Increase salt intake.
  6. Stop smoking.
  7. Walk 30–40 minutes twice weekly.
  8. Take naproxen sodium for headaches.
  9. Answer

    Stop smoking.


    This page titled 18.5: Calcium Channel Blockers was last modified on Sun, 29 Dec 2024 09:21:40 GMT and is shared under a CC BY 4.0 license and was authored, remixed, and/or curated by OpenStax.